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Background: To justify the use of the lidocaine/tetracaine medicated patch or peel as a preventive treatment for 
reducing pain and discomfort in adults and children. We reviewed randomized controlled trials (RCTs) to evaluate 
the efficacy and safety of the lidocaine/tetracaine medicated patch or peel compared with placebo. 
Methods: Ten RCTs (574 patients) were included in this systemic review. Relevant studies were identified through 
searches of MEDLINE, SCOPUS and the Cochrane database library. The outcome was the adequacy of cutaneous 
anesthesia reflected in the patient's assessment of pain intensity during minor dermatologic procedures and adverse 
effects after application of the lidocaine/tetracaine medicated patch or peel versus placebo. 
Results: The efficacy of the lidocaine/tetracaine patch or peel was consistently very significantly beneficial 30 or 60 
minutes after the application compared to placebo (Relative risk, RR: 2.5; Number needed to treat, NNT: 2.2). We 
did not identify any difference in the effectiveness of adequate analgesia between the lidocaine/tetracaine patch and 
peel (the number needed to treat or to harm, NNT 2.4 vs. 2.0). No serious side effects or adverse events were observed 
with the lidocaine/tetracaine medicated patch or peel and placebo. Minor skin reactions were transient and resolved 
without treatment (Odd ratio, OR: 1.4 and 95% confidence interval, CI: 0.9-2.1; NNT: 14.9). 
Conclusions: The lidocaine/tetracaine medicated patch or peel is a well accepted, effective and safe method for 
minor dermatologic procedures based on pooled data of trials in terms of adequacy of cutaneous anesthesia and 
adverse effects. (Korean J Anesthesiol 2012; 62: 435-440)
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Introduction
Pain and discomfort following minor dermatologic pro-
cedures are often underestimated and can be stressful for 
patients. Relieving or preventing such distress is a serious 
clinical concern, especially in children. There are several 
available topical local anesthetics for various dermatologic 
procedures which may be associated with pain or discomfort. 
Hence, topical anesthetics which significantly prevent pain 
and discomfort can be used for minor superficial procedures 
instead of general anesthesia or needle injection of local 
anesthetics. Consequently, even children can better tolerate the 
procedures with lessened anxiety and distress by effective pain 
management. Proper control of pain and discomfort is needed 
to relieve patients’ suffering and produce better outcomes [1,2].
An ideal local anesthetic should be effective, painless 
cutaneous analgesia with a short time of onset, have sufficient 
duration but not have untoward effects. Various options 
have been attempted and developed to overcome the barrier 
of the stratum conium for rapid and effective drug delivery 
with minimal systemic absorption and adverse effects. The 
options include topical application or injection, iontophoresis, 
sonophoresis, laser-assisted transdermal passage, pressurized 
gas delivery and heat-enhanced diffusion [3]. Topical appli-
cation of local anesthetics is currently considered to be the 
easiest, most effective and convenient way for treatment of 
patients who may be undergoing superficial dermal procedures. 
The most commonly used dermal analgesics are lidocaine, 
tetracaine, prilocaine or combinations thereof [3-5]. 
A lidocaine/tetracaine patch (SyneraTM) for topical anesthesia 
as a eutectic 1 : 1 mixture with an oxygen-activated heating 
element has been introduced. This novel drug delivery system 
was developed to warm the skin and improve the delivery 
of local anesthetics through the skin. The same formula was 
designed as a local anesthetic peel (S-Caine Peel) which is 
a pliable peel with a skin-like appearance when exposed to 
air and becomes an easily removable flexible membrane. 
Clinical studies demonstrated that the S-Caine Patch or Peel 
is efficacious in relieving the pain associated with superficial 
dermal procedures [6,7]. 
The objective of this meta-analysis was to examine out-
comes such as adequate analgesic efficacy and safety after 
application of the lidocaine/tetracaine medicated patch or 
peel in published randomized controlled trials (RCTs). We 
identified a considerable number of clinical studies from 
several databases which explored the efficacy and safety of 
the lidocaine/tetracaine medicated patch or peel as a local 
anesthetic for minor dermatologic procedures and minimally 
invasive cutaneous procedures. This report extensively reviewed 
the literature and evaluated the pharmacologic efficacy and 
safety of the patch and peel through the primary outcome of 
pain based on the patient assessment. We found a substantial 
number of published RCTs of the lidocaine/tetracaine patch or 
peel used in different dermatologic procedures and selected 
these according to the method described below. Quantitative 
methods were used to summarize the results, where possible. 
Materials and Methods
A systemic search of the relevant literature was performed 
without language limitations. We mainly searched MEDLINE 
using PUBMED, SCOPUS and the Cochrane database library 
as well as reference lists of reviews or initially identified articles 
which were also used for further articles related to the topic 
[2,4-6,8,9].The search was performed with key words of “topical 
anesthetics”, “s-caine”, “synera” and “lidocaine/tetracaine” in 
their titles or abstracts and electronic searches were conducted 
until October 2010. Inclusion criteria were: (1) prospective RCT 
with full reports on the efficacy and safety of the lidocaine/
tetracaine medicated patch or peel compared with placebo; (2) 
placebo was identical in appearance and had no active drugs, 
and contained the same heating element in the case of patch 
application; (3) investigation was performed in humans (adults 
and children); (4) the measured outcomes (after applying the 
patch or peel 30 or 60 minutes prior to procedures) included 
adequacy of cutaneous anesthesia as well as adverse effects 
after application of the lidocaine/tetracaine medicated patch 
or peel; (5) the patient's assessment of pain intensity during 
the minor dermatologic procedures such as needle insertion, 
laser treatment and IV cannulation, etc. We did not include 
data from abstracts, posters, case reports, letters to the editor, 
reviews or animal research. Only prospective randomized, 
double-blinded, placebo controlled trials that evaluated the 
efficacy and safety of the lidocaine/tetracaine medicated patch 
or peel were included. More invasive procedures involving 
skin incision, graft and trials investigating topical application 
of mucous membrane and open wounds were excluded. No 
attempts were made to obtain unpublished studies or did we 
request for unpublished data from any company developing 
related drugs. 
Selected reports were examined and scored using the five-
point Oxford scale for assessment of validity by one of the 
authors [1,10]. Collected data were recorded on formalized 
sheets and we converted the adequacy of anesthesia originally 
presented as a percentage of the number of patients for 
analysis, where needed. We computed relative benefits (RB) as 
relative risks (RR) of the lidocaine/tetracaine medicated patch 
or peel with 95% confidence intervals (CI). We calculated the 
number needed to treat or to harm (NNT) as a useful estimated 
measure of a significant clinical effect. NNT is the number of 
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patients that must be treated with an experimental intervention 
(the lidocaine/tetracaine medicated patch or peel) to achieve 
a particular result (beneficial or harmful) in one of them which 
would not have been the case had they all received the control 
interventions (placebo). Many studies on adverse effects 
had zero cells (i.e., trials had no report on any event in one of 
the study groups) that odds ratio (OR) with 95% confidence 
intervals was presented. Statistical analysis was performed 
using MIX 1.7 for Windows that was developed and validated by 
Leon Bax of the Department of Medical Informatics of Kitasato 
University in Japan [11,12].
Results
We identified 16 randomized controlled trials and included 
10 of them in the present systemic review, thereby enrolling 
a total 574 subjects [7,13-23]. Among the six other studies, 
one article had no accessible dichotomous data on safety and 
efficacy with only P values [20]. Five other studies compared 
S-caine and EMLA or 2% lidocaine, which was an inappropriate 
placebo for our review, and one of them tested the contribution 
of a heating element to the topical patch [14,24-27]. A detailed 
summary of each trial, including methodological quality 
scores, is presented in Table 1. The median quality of score was 
3 in two trials, 4 in two and 3 in six. Two papers which scored 
5 reported appropriate description of randomizations (i.e., 
computer-generated or table of random number) and blinding 
(i.e., an active and indistinguishable placebos were used) [7,23]. 
Most trials used VAS to measure the adequacy of anesthesia. 
Surrogate pain scores provided by investigators, parents or 
observers were not included in the analysis.
Data were pooled for calculation and computed for com-
bining analysis. All trials showed positive effects for the 
adequacy of cutaneous anesthesia (Fig. 1). Cochran Q statistic 
P value (0.4) was above 0.05, demonstrating homogeneity in the 
trials. As a result, a fixed-effects model with a weighting method 
(inverse variance) developed by DerSimonian and Laird was 
used. Relative risk (relative benefit) was 2.5 (95% confidence 
interval 2.0-3.1) and efficacy of cutaneous anesthesia by 
the lidocaine/tetracaine medicated patch or peel compared 
to placebo was highly significant (P < 0.01: Fig. 1). NNT for 
effectiveness of adequacy of anesthesia was calculated as 2.2. 
Subgroup analysis results are shown in Table 2. Subgroups were 
similar with each other in terms of homogeneity, effects model 
and NNT. They consistently showed highly significant benefits 
of the lidocaine/tetracaine medicated patch or peel compared 
to placebo. 
Eight trials reported on adverse effects which included 
erythema, burning sensation, itching, blisters and edema 
in both groups [13,16-19,21-23]. No weighting was used for 
different grades of adverse effects. Mild erythema was the 
most often observed adverse effect, but all adverse events were 
transient and resolved without treatment. Slight blanching was 
noted but no delayed allergic skin reactions were observed. 
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Table 2. Pooled and Separated Analysis of Effects Based on Application Type







Fixed effects model (P < 0.01)
Fixed effects model (P < 0.01) 







RR: Relative risk, CI: Confidence interval, NNT: The number needed to treat or to harm.
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There were no severe adverse events and no trials presented 
any significant difference between the lidocaine/tetracaine 
patch or peel and placebo (Fig. 2). The lower limit of the 95% 
confidence interval (CI) was 0.9 (OR < 1) that reported adverse 
effects showed no differences between the lidocaine/tetracaine 
medicated patch or peel and placebo. NNT for the adverse 
cutaneous effects was calculated as 14.9.
Discussion
Several methods are available to ease pain or discomfort 
for minor dermatologic procedures [28]. Application of the 
lidocaine/tetracaine medicated patch or peel to the skin 30 or 60 
minutes before procedures may be an effective and safe means 
of anesthesia. Moreover, both the patch and peel formulation 
types provide convenient, noninvasive and painless means of 
application, with a rapid onset, minimal adverse effects, without 
the need for occlusion and easy removal [19,22]. Many clinical 
trials confirmed these potential advantages [7,13,15,16,19,21-
23]. However, a comprehensive literature analysis has not yet 
performed to test the hypothesis that the lidocaine/tetracaine 
medicated patch or peel is indeed an effective and safe method 
for reducing procedural pain. The present systemic review 
addressed the efficacy by comparing the patch or peel to 
placebo. Ten randomized, controlled trials were combined, and 
the data were statistically homogenous so a fixed effects model 
was used. Thus, we were able to draw a conclusion that the 
lidocaine/tetracaine medicated patch or peel was consistently 
and significantly more efficacious than placebo, based on 
subject-reported pain intensity, using the VAS scores. 
A patch delivery system provides a specific amount of drug 
to a clearly distinct dermal area and is easier to apply and 
remove than the peel formula. Half the trials were with a patch 
formula, and the other half examined peel type applications. 
A transdermal patch included an oxygen-activated heating 
pad containing lidocaine and tetracaine [7,22]. This newly-
developed drug delivery system uses controlled heat to enhance 
the delivery of local anesthetics through the skin. But the system 
was not found superior to the peel type application in this 
review. There was not much difference in efficacy and safety 
between subgroups of the lidocaine/tetracaine medicated patch 
and peel for dermal anesthesia over intact skin. Patches were 
administered for 20 minutes in 2 trials and for 30 minutes in 2 
trials and for 39 minutes in 1 trial. For the peel type applications, 
they were administered for 30 minutes in 2 trials and for 60 
minutes in 3 trials. Similar outcomes of RR and NNT might be 
Fig. 1. An annotated forest plot (adequacy of cutaneous anesthesia) shows individual trials, depicted as filled squares, with the relative size of 
weights and horizontal bars as the confidence interval. The bottom diamond shape refers to the pooled value. RR: relative risk.
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attributed to the fact that the duration time of application was 
not considered in this review. It will be necessary to determine 
the impact of a heating component on the onset time with 
RCTs. 
Adverse effects of the lidocaine/tetracaine medicated patch 
and peel were limited to transient mild erythema, blister, 
burning sensation, itching and edema. Even though the adverse 
effects were considered to be moderate in severity, they were 
resolved without intervention. Patch type formulas showed 
slightly more erythema and edema than placebo due to the 
vasodilating action of tetracaine and local heating system of 
the patch [9,21-23]. However, the difference in frequency was 
small so that the incidence of adverse effects of the medicated 
patch and peel was not significantly different from placebo, 
even when comparing 4 trials with the patch-type application. 
The potential for systemic absorption of tetracaine and 
lidocaine through intact skin is insignificant because blood 
concentrations of tetracaine and lidocaine were reported to 
be below the lower limit of quantitation [8,18]. The use of a 
medicated patch and peel was judged safe in this review. 
There is a limitation of this study. Although we tried to 
minimize publication bias during arranging the process of 
review, there exist possible sources of error. Publication bias 
(Egger's regression method, P < 0.01), the tendency of studies 
with positive results to be accepted as well as negative reports to 
be rejected, may alter the study outcome. 
We concluded that the lidocaine/tetracaine medicated patch 
and peel were highly efficacious and safe in reducing local pain 
when applied 60 minutes prior to minor dermal procedures. 
Indeed, our results indicated that the patch and peel formula 
provided several potential clinical advantages such as minimal 
adverse effects and adequate dermal anesthesia in both adult 
and pediatric patients. Further trials are warranted to assess 
the effects of a heating drug delivery system on topical dermal 
anesthesia, prolongation of duration and reduction of the time 
of onset. Further, well-designed clinical trials are needed to 
compare the formulas with EMLA, liposome-encapsulated 
lidocaine or tetracaine, and BLT: triple anesthetic gel. 
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